Document:

*** Certain information (indicated by an asterisk) has been omitted from this
document pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

                                                                 Exhibit 10.9(b)

                               Amendment No. 1 to

                           Agreement on Joint Actions
                                   *** and
                      "American Biogenetic Sciences, Inc."
                             Dated January 14, 2002

Moscow, Russia                                                   March 11, 2002.

1. Additional text is to be added to Section 6 as follows:

   "*** reserves the right to terminate from this agreement the anthrax vaccine
   if in the one (1) year period after the registration and other approval for
   sale in the United States "American Biogenetic Sciences, Inc." fails to
   purchase the minimum amount of 1,000,000 doses of the anthrax vaccine."

2. Additional Paragraph is to be added to Section 6 as follows:

   "*** has an agreement with the producer of the vaccine smallpox in tablets
   live for preoral application granting it the exclusive right to sell and
   distribute the vaccine smallpox in tablets live for preoral application
   throughout the world and *** hereby grants "American Biogenetic Sciences,
   Inc." the exclusive right to sell and distribute the vaccine smallpox in
   tablets live for preoral application for a period of ten (10) years in
   consideration for the efforts, costs and expenses to be incurred by "American
   Biogenetic Sciences, Inc." to attempt obtaining certification, registration
   and other approval of the vaccine smallpox in tablets live for preoral
   application in the United States of America. "American Biogenetic Sciences,
   Inc." pledges to purchase not less than 1,000,000 doses annually (for
   immunization of 1,000,000 patients) pursuant to Section 3, once registration
   of the vaccine smallpox in tablets live for preoral application is approved
   for sale in the United States. *** reserves the right to terminate from this
   agreement the vaccine smallpox in tablets live for preoral application if in
   the one (1) year period after the registration and other approval for sale in
   the United States "American Biogenetic Sciences, Inc." fails to purchase the
   minimum amount of 1,000,000 doses of the vaccine smallpox in tablets live for
   preoral application."

------------------
*** Certain information (indicated by an asterisk) has been omitted from this
document pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

Page 1

<PAGE>

3. Section 7 of the agreement shall be deleted in its entirety and replaced with
the following language:

   "7.Nothing in this agreement shall be construed as imposing on "American
   Biogenetic Sciences, Inc." an obligation to deal exclusively with *** in
   respect of any of the preparations, excluding the anthrax vaccine and vaccine
   smallpox in tablets live for preoral application, provided *** can provide
   "American Biogenetic Sciences, Inc.", within one year of the date of this
   agreement, with an acceptable anthrax vaccine and vaccine smallpox in tablets
   live for preoral application that meets all necessary quality and
   manufacturing standards, and is reasonably price competitive necessary to
   market the anthrax vaccine and vaccine smallpox in tablets live for preoral
   application within the United States."

4. All other terms and conditions of the agreement shall remain in full force
and effect.

***                                 Chairman and CEO
***                                 American Biogenetic
Sciences, Inc.

  /s/ ***        ***                   /s/ A.J. Roach    A.J.Roach
----------------                    ------------------

------------------
*** Certain information (indicated by an asterisk) has been omitted from this
document pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

Page 2EXHIBIT 10.78

                 AMENDMENT NO. 1 AND WAIVER TO CREDIT AGREEMENT

     This  Amendment No. 1 and Waiver (this  "Amendment  and Waiver") is entered
into as of July 13, 2001 by and among TRIMBLE  NAVIGATION  LIMITED, a California
corporation (the "Company"),  the institutions  from time to time parties hereto
as Lenders,  ABN AMRO BANK,  N.V. in its capacity as  administrative  agent (the
"Administrative  Agent") for itself and the other Lenders,  FLEET NATIONAL BANK,
as Syndication Agent (the "Syndication  Agent"), and THE BANK OF NOVA SCOTIA, as
Documentation Agent (the "Documentation Agent").

                                    RECITALS

     A. The Company, the Agents and the Lenders are party to that certain Credit
Agreement dated as of July 14, 2000 (the "Credit  Agreement").  Unless otherwise
specified herein, capitalized terms used in this Amendment and Waiver shall have
the meanings ascribed to them by the Credit Agreement.

     B. The Company  wishes to issue  Capital  Stock for up to $40 million on or
before December 31, 2001 (the "Equity Issuance").

     C. On and  subject to the terms and  conditions  hereof,  the  Company  has
requested  that the Agents and the  Lenders,  and the Agents and the Lenders are
willing to, (i) waive compliance with certain financial covenants for the period
ended June 29, 2001, (ii) amend certain provisions of the Credit Agreement,  and
(iii) agree as to the  application  of the Net Proceeds of the Equity  Issuance,
all as set forth herein.

     Now,  therefore,  in consideration of the mutual execution hereof and other
good and valuable consideration, the parties hereto agree as follows:

     1. Amendments to Credit  Agreement.  Upon the "Effective  Date" (as defined
below), the Credit Agreement shall be amended as follows:

     (a)  The  definition  of  "Fixed  Charges"  in  Section  1.1 of the  Credit
Agreement  shall be amended by adding the following  phrase before the period at
the end thereof:

     "minus (e) for  purposes  of  calculating  "Fixed  Charges"  for the fiscal
quarter ending  September 30, 2001, any amounts paid by Seller or its affiliates
to reduce the purchase  price of the stock and assets  pursuant to the Stock and
Asset Purchase Agreement during such quarter."

     (b)  Section  2.15(d)(ii)  of the  Credit  Agreement  shall be  amended  by
deleting the table contained therein and replacing such table with the following
table:
<TABLE>
<CAPTION>
===================================== =================== ================================= ==========================
                                          APPLICABLE
                                        FLOATING RATE                                         APPLICABLE COMMITMENT
           LEVERAGE RATIO                   MARGIN         APPLICABLE EUROCURRENCY MARGIN        FEE PERCENTAGE
------------------------------------- ------------------- --------------------------------- --------------------------
------------------------------------- ------------------- --------------------------------- --------------------------
<S>                                        <C>                        <C>                           <C>
Less than 1.50                              0.25%                      1.25%                         0.375%
------------------------------------- ------------------- --------------------------------- --------------------------
------------------------------------- ------------------- --------------------------------- --------------------------
1.50 or greater, but less than 2.00         0.75%                      1.75%                         0.375%
------------------------------------- ------------------- --------------------------------- --------------------------
------------------------------------- ------------------- --------------------------------- --------------------------
2.00 or greater, but less than 2.50         1.25%                      2.25%                         0.500%
------------------------------------- ------------------- --------------------------------- --------------------------
------------------------------------- ------------------- --------------------------------- --------------------------
</TABLE>

                                       99
<PAGE>
<TABLE>
<CAPTION>
===================================== =================== ================================= ==========================
                                          APPLICABLE
                                        FLOATING RATE                                         APPLICABLE COMMITMENT
           LEVERAGE RATIO                   MARGIN         APPLICABLE EUROCURRENCY MARGIN        FEE PERCENTAGE
------------------------------------- ------------------- --------------------------------- --------------------------
------------------------------------- ------------------- --------------------------------- --------------------------
<S>                                        <C>                        <C>                           <C>
2.50 or greater, but less than 2.75         1.75%                      2.75%                         0.500%
------------------------------------- ------------------- --------------------------------- --------------------------
------------------------------------- ------------------- --------------------------------- --------------------------
2.75 or greater, but less than 3.00         2.00%                      3.00%                         0.500%
------------------------------------- ------------------- --------------------------------- --------------------------
------------------------------------- ------------------- --------------------------------- --------------------------
3.00 or greater                             2.25%                      3.25%                         0.500%
===================================== =================== ================================= ==========================
</TABLE>

     (c) Section 5.3(a) of the Credit Agreement shall be amended by inserting at
the end of such  Section  the text "and no Default or  Unmatured  Default  would
result after  giving  effect to the making of any Loan or issuance of any Letter
of Credit."

     (d) Section 7.4(a) of the Credit Agreement shall be deleted in its entirety
and replaced with the following new Section 7.4(a):

          (a) Minimum Fixed Charge Coverage Ratio. The Company shall maintain as
     of the end of each  fiscal  quarter  set forth  below  (i) for each  fiscal
     quarter  ending on or after  September  30, 2002,  a Fixed Charge  Coverage
     Ratio for the four fiscal  quarter  period then  ending,  and (ii) for each
     fiscal quarter  ending on or before June 30, 2002, a Fixed Charge  Coverage
     Ratio for such fiscal  quarter,  of not less than the ratio set forth below
     opposite such period:

                         Fiscal Quarter Ending                       Ratio
                         ---------------------                       -----
        September 30, 2001                                         1.00:1.00
        December 31, 2001 through March 31, 2003                   1.20:1.00
        June 30, 2003                                              1.50:1.00
        September 30, 2003                                         1.75:1.00
        December 31, 2003                                          2.00:1.00
        March 31, 2004 and June 30, 2004                           2.25:1.00
        September 30, 2004 and thereafter                          2.50:1.00

     (e) Section 7.4(b) of the Credit Agreement shall be deleted in its entirety
and replaced with the following new Section 7.4(b):

          (b) Maximum  Leverage Ratio. The Company shall at all times during the
     periods  specified  below  maintain  a Leverage  Ratio for the four  fiscal
     quarter  period then  ending of not greater  than the ratio set forth below
     opposite such period:

                          Fiscal Quarter Ending                      Ratio
                          ---------------------                      -----
         September 30, 2001                                        3.90:1.00
         December 31, 2001                                         3.25:1.00
         March 31, 2002                                            2.50:1.00
         June 30, 2002                                             2.00:1.00
         September 30, 2002                                        1.75:1.00
         December 31, 2002 and thereafter                          1.50:1.00

     2. Waiver.  Subject to the conditions and  effectiveness  of this Agreement
and otherwise notwithstanding the provisions of any Loan Document, the Agent and
the Lenders hereby waive (a) any Default arising under Section  8.1(b)(i) of the
Credit Agreement  resulting solely from the Company's failure to comply with the
financial covenants set forth in Sections 7.4(a) and (b) of the Credit Agreement
for the period of four fiscal  quarters  ended June 29, 2001 and (b) solely with
respect to the  prepayment  referenced  in Section 6(d) of this  Agreement,  the
notice requirements set forth in Section 2.5(a) of the Credit Agreement.

                                      100
<PAGE>

     3. Agreement With Respect to Application of Certain Mandatory  Prepayments.
In addition to the prepayment referenced in Section 6(d) of this Agreement,  the
Company,  the  Agents  and the  Lenders  hereby  agree that 50% of the first $20
million of Net Proceeds of the Equity Issuance  immediately  shall be applied to
prepay  the Term Loans in the  manner  set forth in  Section  2.5(b)(ix)  of the
Credit Agreement. The Agents and the Lenders hereby waive any requirement in the
Credit  Agreement  that the  remaining  Net  Proceeds of the Equity  Issuance be
applied to repay the Term Loan;  provided  that no Default or Unmatured  Default
exists at the time of such Equity Issuance.

     4. Agreement With Respect to Equity  Issuance.  The Company agrees that the
Equity Issuance will be on terms and conditions  reasonably  satisfactory to the
Agents.

     5.  Representations  and Warranties of the Company.  The Company represents
and warrants that:

     (a) it has the requisite power and authority and legal right to execute and
deliver this Amendment and Waiver and to perform its obligations hereunder.  The
execution  and  delivery  by the  Company of this  Amendment  and Waiver and the
performance of its  obligations  hereunder  have been duly  authorized by proper
proceedings,  and this  Amendment  and  Waiver  constitutes  a legal,  valid and
binding obligation of the Company  enforceable against it in accordance with its
terms, except as enforceability may be limited by any bankruptcy,  insolvency or
similar law affecting the enforcement of creditors' rights generally;

     (b) Each of the  representations  and  warranties  contained  in the Credit
Agreement  and the other Loan  Documents  is true and  correct  in all  material
respects on and as of the date hereof as if made on the date hereof; and

     (c) After  giving  effect to this  Amendment  and  Waiver,  no  Default  or
Unmatured Default has occurred and
is continuing.

     6. Effective Date. This Amendment and Waiver shall become  effective on the
date (the "Effective Date") on which each of the following items shall have been
received by Administrative  Agent or satisfied,  as the case may be, all in form
and substance satisfactory to the Administrative Agent:

     (a) duly executed Amendment and Waiver, executed by the Company, the Agents
and the Required Lenders (without respect to whether it has been executed by all
the Lenders);

     (b) a reaffirmation  of guaranty in form and substance  satisfactory to the
Administrative Agent, duly executed by each Guarantor;

     (c)  payment  of an  amendment  fee to the  Administrative  Agent,  for the
ratable  benefit of each Lender  signatory to this  Amendment and Waiver,  in an
amount equal to 0.200% of the Aggregate Commitment as of June 30, 2001;

     (d)  permanent  prepayment  of the  Term  Loan in an  amount  equal  to $10
million,  which  shall be  applied to the  outstanding  balance of the Term Loan
against all  remaining  scheduled  principal  installments  in inverse  order of
maturity ; and

     (e) such other  documents  as the  Administrative  Agent or its counsel may
have reasonably requested.

     7. Reference to and Effect Upon the Credit Agreement.

     (a) Except as  specifically  amended  above,  the Credit  Agreement and the
other  Loan  Documents  shall  remain in full  force and  effect  and are hereby
ratified and confirmed.

     (b) The execution,  delivery and effectiveness of this Amendment and Waiver
shall not operate as a waiver of any other  right,  power or remedy of any Agent
or Lender under the Credit Agreement or

                                      101
<PAGE>

any other Loan  Document,  or constitute a waiver of any provision of the Credit
Agreement or any Loan Document,  except as specifically  set forth herein.  Upon
the  effectiveness  of this  Amendment and Waiver,  each reference in the Credit
Agreement to "this Agreement",  "hereunder", "hereof" or words of similar import
shall mean and be a reference  to the Credit  Agreement as amended  hereby,  and
each  reference in the other Loan Documents to the Credit  Agreement  shall mean
and be a reference to the Credit Agreement as amended hereby.

     8. Costs and Expenses.  The Company  hereby  affirms its  obligation  under
Section 11.6 of the Credit Agreement to reimburse the  Administrative  Agent for
all reasonable costs and out-of-pocket expenses (including reasonable attorneys'
and  paralegals'  fees and time  charges of  attorneys  and  paralegals  for the
Administrative Agent) paid or incurred by the Administrative Agent in connection
with the preparation,  negotiation,  execution, delivery,  syndication,  review,
proposed or completed amendment,  waiver or modification,  and administration of
the Loan Documents.

     9.  GOVERNING LAW. ANY DISPUTE  BETWEEN THE COMPANY AND THE  ADMINISTRATIVE
AGENT,  ANY LENDER OR ANY OTHER HOLDER OF OBLIGATIONS  ARISING OUT OF, CONNECTED
WITH, RELATED TO, OR INCIDENTAL TO THE RELATIONSHIP  ESTABLISHED BETWEEN THEM IN
CONNECTION  WITH,  THIS AMENDMENT AND WAIVER OR ANY OF THE OTHER LOAN DOCUMENTS,
AND WHETHER ARISING IN CONTRACT,  TORT, EQUITY, OR OTHERWISE,  SHALL BE RESOLVED
IN  ACCORDANCE  WITH THE INTERNAL  LAWS (BUT WITHOUT  REGARD TO THE CONFLICTS OF
LAWS PROVISIONS) OF THE STATE OF ILLINOIS.

     10.  Headings.  Section  headings in this Amendment and Waiver are included
herein for convenience of reference only and shall not constitute a part of this
Amendment and Waiver for any other purposes.

     11.  Counterparts.  This Amendment and Waiver may be executed in any number
of counterparts,  each of which when so executed shall be deemed an original but
all of such counterparts shall constitute one and the same instrument.

                            [signature pages follow]

                                      102
<PAGE>

     IN WITNESS WHEREOF,  the Company,  the Lenders and the Agents have executed
this Amendment and Waiver of the date first above written.

                  TRIMBLE NAVIGATION LIMITED, as the Company

                  By: /s/ Mary Ellen Genovese
                     -------------------------------------------------------
                       Name: Mary Ellen Genovese
                       Title: CFO

                  ABN AMRO BANK N.V., as Administrative Agent, Issuing Bank,
                  Swing Line Bank, Alternate Currency Bank, and Lender

                  By: /s/ Ruby P. Galang
                      -------------------------------------------------------
                       Name: Ruby P. Galang
                       Title: Vice President

                  By: /s/ John Hill
                      -------------------------------------------------------
                       Name: John Hill
                       Title: Assistant Vice President

                  FLEET NATIONAL BANK, as Syndication Agent and Lender

                  By: /s/ Lee A Merkle-Raymond
                      -------------------------------------------------------
                       Name: Lee A Merkle-Raymond
                       Title: Director

                  THE BANK OF NOVA SCOTIA, as
                  Documentation Agent and Lender

                  By: /s/ Chris Osborn
                      -------------------------------------------------------
                       Name: Chris Osborn
                       Title: Director

                  ERSTE BANK, NEW YORK BRANCH, as Lender

                  By: /s/ Robert L.Wagman
                      -------------------------------------------------------
                       Name: Robert L. Wagman
                       Title: Vice President

                  By: /s/ Ruth S. Burrton
                      -------------------------------------------------------
                      Name: Ruth S. Burrton

                                      103
<PAGE>

                  Title: Managing Director

                  WELLS FARGO BANK, as Lender

                  By: ---------------------------------------------------
                       Name:
                       Title:

                  MERITA BANK PLC, NEW YORK BRANCH, as Lender

                  By: /s/ Ulf Forstrom
                  -------------------------------------------------------
                    Name: Ulf Forstrom
                    Title: Vice President

                  By: /s/ Henrik Brink
                  -------------------------------------------------------
                    Name: Henrik Brink
                    Title: Vice President

                  BANK OF THE WEST, as Lender

                  By:----------------------------------------------------
                      Name:
                      Title:

                  BARCLAYS BANK PLC, as Lender

                   By: /s/ Sydney G. Dennis
                       -------------------------------------------------------
                         Name: Sydney G. Dennis
                         Title: Director

                   NATIONAL CITY BANK OF KENTUCKY, as Lender

                   By:-------------------------------------------------------
                        Name:
                        Title:

                   IBM CREDIT CORPORATION, as Lender

                   By: /s/ Thomas S. Curcio
                       -------------------------------------------------------
                          Name: Thomas S. Curcio
                          Title: Manager of Credit

                                      104
<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]